YD Bio Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2024	FY 2023	FY 2022
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022
Net Income	-1.41	0.01	-0.05
Depreciation & Amortization	0.1	0	0
Loss (Gain) From Sale of Assets	-	0	-
Loss (Gain) From Sale of Investments	-	-	0.06
Provision & Write-off of Bad Debts	-0	0	-0
Other Operating Activities	0.04	0.05	0.06
Change in Accounts Receivable	-0.01	-0.06	0.1
Change in Inventory	0.03	-0.03	-0
Change in Accounts Payable	0.01	0.01	-0.01
Change in Other Net Operating Assets	-0.6	-0.04	-0.08
Operating Cash Flow	-1.84	-0.06	0.07
Capital Expenditures	-0.07	-0	-
Sale (Purchase) of Intangibles	-2.84	-	-
Investment in Securities	0.01	-	-0.07
Investing Cash Flow	-2.9	-0	-0.07
Short-Term Debt Issued	0.31	0.15	0.01
Total Debt Issued	0.31	0.15	0.01
Short-Term Debt Repaid	-0.1	-	-0.05
Long-Term Debt Repaid	-0.03	-0.03	-0.03
Total Debt Repaid	-0.13	-0.03	-0.08
Net Debt Issued (Repaid)	0.18	0.11	-0.07
Issuance of Common Stock	7.55	-	-
Financing Cash Flow	7.73	0.11	-0.07
Foreign Exchange Rate Adjustments	0.06	-0	-0.01
Net Cash Flow	3.05	0.06	-0.08
Free Cash Flow	-1.91	-0.06	0.07
Free Cash Flow Margin	-374.58%	-15.98%	19.21%
Free Cash Flow Per Share	-1.75	-0.05	-
Cash Interest Paid	0	0	0
Levered Free Cash Flow	-3.88	0.06	-
Unlevered Free Cash Flow	-3.88	0.07	-
Change in Working Capital	-0.57	-0.13	0

Updated Apr 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q